Intuitive Surgical, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Intuitive Surgical, Inc. stock analysis ISRG overview
Somewhat Bullish +45

ABN AMRO Bank N.V. Sells 23,961 Shares of Intuitive Surgical, Inc ...

📉 ABN AMRO Bank N.V. decreased its ISRG position by 37.1% in Q1, selling 23,961 shares while retaining a stake valued at $18.89 million.

📈 Several smaller hedge funds including Riversedge Advisors LLC and WoodTrust Financial Corp increased their stakes in the fourth quarter.

📊 Intuitive Surgical reported Q1 revenue of $2.77 billion, representing a 23% year-over-year increase compared to analyst expectations of $2.62 billion.

💰 The company posted earnings per share of $2.50, significantly topping the consensus estimate of $2.08 with a net margin of 28.15%.

📉 Analyst sentiment is mixed with recent downgrades from Zacks Research and UBS Group lowering price targets to $558 and $550 respectively.

🏦 The stock maintains a consensus 'Moderate Buy' rating with an average target price of $573.42 based on 19 buy, 7 hold, and 1 sell ratings.

📉 Insider selling activity was significant in April and June, with directors and SVPs reducing holdings via pre-arranged Rule 10b5-1 trading plans.

📈 The company has a market capitalization of $143.33 billion and trades at a P/E ratio of 49.05.

🔬 Intuitive Surgical is best known for its da Vinci surgical systems which enable minimally invasive procedures in hospitals and surgical centers.

📉 The stock opened at $404.70, trading below its 50-day moving average of $432.67 and 200-day moving average of $484.61.

Bullish Signals
  • Intuitive Surgical reported Q1 revenue of $2.77 billion, a 23% year-over-year increase that exceeded analyst expectations of $2.62 billion.
  • The company posted earnings per share of $2.50, beating the consensus estimate of $2.08 by $0.42.
  • Intuitive Surgical achieved a strong net margin of 28.15% and a return on equity of 15.98% for the quarter.
  • The stock maintains a consensus 'Moderate Buy' rating from nineteen equities research analysts with a target price of $573.42.
Risk Factors
  • Zacks Research lowered its rating on Intuitive Surgical from 'strong-buy' to 'hold' in a report dated March 30th.
  • UBS Group decreased its price target from $570.00 to $550.00 and set a 'neutral' rating in a report dated March 17th.
  • Bank of America dropped its price target from $520.00 to $515.00 in a research note dated June 12th.
  • Major institutional investor ABN AMRO Bank N.V. significantly reduced its position by 37.1% during the first quarter.
  • Insiders sold a total of 7,169 shares valued at $3.06 million over the last quarter, indicating some internal profit-taking.
Full Analysis
Intuitive Surgical (NASDAQ:ISRG) saw a mixed institutional landscape in the first quarter, highlighted by ABN AMRO Bank N.V. reducing its stake by 37.1% to 40,572 shares, worth approximately $18.9 million. Conversely, several smaller hedge funds including Riversedge Advisors LLC and Fiduciary Financial Group LLC increased their positions slightly during the fourth quarter, while WoodTrust Financial Corp also added to its holdings. Analyst sentiment remains cautiously positive despite recent downgrades from major firms like Zacks Research and UBS Group, which lowered price targets. The consensus rating is a 'Moderate Buy' with a target price of $573.42, though the stock recently traded below its 50-day moving average. Insider selling activity was notable in April and June, with directors and senior executives executing pre-arranged Rule 10b5-1 trades to reduce their personal holdings. Financially, Intuitive Surgical delivered strong performance in the quarter ending April 21st, reporting revenue of $2.77 billion, a 23% year-over-year increase that beat analyst expectations. The company posted earnings per share of $2.50 against a consensus of $2.08, resulting in a net margin of 28.15%. With a market capitalization of $143.33 billion and a P/E ratio of 49.05, the medical robotics leader continues to demonstrate robust growth driven by its da Vinci surgical systems.